Craig-Hallum Gives a Buy Rating to LifeMD (LFMD)

In a report released today, Alex Fuhrman from Craig-Hallum assigned a Buy rating to LifeMD (LFMD – Research Report). The company’s shares closed yesterday at $5.16.

Fuhrman covers the Consumer Cyclical sector, focusing on stocks such as Life Time Group Holdings, WW International, and Lands’ End. According to TipRanks, Fuhrman has an average return of -3.5% and a 39.06% success rate on recommended stocks.

Currently, the analyst consensus on LifeMD is a Strong Buy with an average price target of $12.00.

LFMD market cap is currently $222.2M and has a P/E ratio of -7.37.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LFMD in relation to earlier this year. Last month, Stefan Galluppi, the Chief Innovation Officer of LFMD bought 3,000.00 shares for a total of $14,790.00.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

LifeMD (LFMD) Company Description:

Conversion Labs, Inc. engages in the manufacturing, distribution, and sale of natural immune support products containing proprietary yeast beta glucans. Its products are oral intake tablets and topical creams, and gels for skin application. It operates through the Finished Cosmetic Products and Nutraceutical and Cosmetic Additives segments. The company was founded in 1987 and is headquartered in New York, NY.